AL3818

DRUG5 trials

Conditions

Alveolar Soft Part SarcomaCervical CancerCervical CarcinomaEndometrial CancerEndometrial CarcinomaFallopian Tube CarcinomaGynecologic CancerLeiomyosarcoma

Phase 1

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)

TerminatedNCT02558348

Advenchen Laboratories, LLCCervical Cancer, Endometrial Cancer, Ovarian Cancer

Start: 2015-11-30End: 2017-05-30Updated: 2019-06-19

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Active, not recruitingNCT04165330

Sarcoma Oncology Research Center, LLCNon Small Cell Lung Cancer, Small Cell Lung Cancer, Soft Tissue Sarcoma +1

Start: 2019-10-17End: 2028-03-31Target: 56Updated: 2025-02-24

Phase 3

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

NCT02584478

Advenchen Laboratories, LLCCervical Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma +2

Start: 2015-12-31End: 2024-12-31Updated: 2023-11-08

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)

RecruitingNCT03016819

Advenchen Laboratories, LLCAlveolar Soft Part Sarcoma, Leiomyosarcoma, Soft-Tissue Sarcoma +1

Start: 2017-08-15End: 2028-12-01Target: 325Updated: 2026-02-25

Unknown Phase

Catequentinib in Patients Who Have Completed an Advenchen Study (A Compassionate Use Trial)

NCT05612191

Advenchen Laboratories, LLCGynecologic Cancer, Sarcoma,Soft Tissue

Updated: 2022-11-28

Related Papers

A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).

Journal of Clinical Oncology2025-05-281 citations

TP035/#1557 Phase 3 study assessing the efficacy of adding AL3818 (catequentinib dihydrochloride, anlotinib hydrochloride) to chemotherapies in subjects with platimum resistant and refractory ovarian carcinoma

2022-12-01

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.

Journal of Clinical Oncology2021-05-2025 citations

Safety and PK results from a phase Ib study of AL3818 (anlotinib) hydrochloride in subjects with ovarian, cervical, and endometrial cancers.

Journal of Clinical Oncology2017-05-208 citations